

Figure S2. ^{29}Si NMR spectra of silylated tyrosinamide using DIEA as base

^{29}Si NMR (99.4MHz, DMSO- d_6 , 25°C): $\delta(\text{ppm})$ -45.0




Figure S3. ^1H NMR spectra of silylated tyrosinamide using NaHCO_3 as base

^1H RMN (500MHz, DMSO- d_6 , 25°C): $\delta(\text{ppm})$ 0.49 (m, 2H, H_3) ; 1.13 (t, 9H, $J = 7.0$ Hz, H_1) ; 1.36 (m, 2H, H_4) ; 2.62 (dd, 1H, $J = 7.5$ Hz, 13.8 Hz, H_{10a}) ; 2.78 (dd, 1H, $J = 5.3$ Hz, 13.8 Hz, H_{10b}) ; 2.90 (q, 2H, $J = 6.4$ Hz, H_5) ; 3.73 (q, 6H, $J = 7.0$ Hz, H_2) ; 4.22 (m, 1H, H_8) ; 5.84 (d, 1H, $J = 8.2$ Hz, H_7) ; 6.09 (t, 1H, $J = 5.4$ Hz, H_6) ; 6.62 (d, 2H, $J = 8.5$ Hz, H_{11}) ; 6.94 (d, 2H, $J = 8.4$ Hz, H_{12}) ; 6.96 (s, 1H, H_{9a}) ; 7.35 (s, 1H, H_{9b}).

Compound 2:




Figure S4. ¹H NMR spectra of silylated serinamide using DIEA as base

¹H RMN (500MHz, DMSO-d₆, 25°C): δ(ppm) 0.52 (m, 2H, H₃) ; 1.14 (t, 9H, J = 7.0 Hz, H₁) ; 1.28 (m, 17H, CH₃ DIEA) ; 1.39 (m, 2H, H₄) ; 2.94 (q, 2H, J = 7.0 Hz, H₅) ; 3.10 (q, 3H, J = 7.5 Hz, CH₂ DIEA) ; 3.45 (m, 1H, H_{10a}) ; 3.58 (m, 3H, H_{10b} + 2CH DIEA) ; 3.73 (q, 6H, J = 7.0 Hz, H₂) ; 4.04 (m, 1H, H₈) ; 4.86 (t, 1H, J = 5.3 Hz, H₁₁) ; 6.00 (d, 1H, J = 7.8 Hz, H₇) ; 6.27 (t, 1H, J = 5.5 Hz, H₆) ; 6.99 (s, 1H, H_{9a}) ; 7.22 (s, 1H, H_{9b}) ; 9.52 (s, 1H, NH⁺ DIEA).

Residual DIEA: 25%




Figure S5. ¹H NMR spectra of silylated serinamide using NaHCO₃ as base

¹H RMN (500MHz, DMSO-d₆, 25°C): δ(ppm) 0.52 (m, 2H, H₃) ; 1.14 (t, 9H, J = 7.0 Hz, H₁) ; 1.39 (m, 2H, H₄) ; 2.94 (q, 2H, J = 7.0 Hz, H₅) ; 3.45 (m, 1H, H_{10a}) ; 3.58 (m, 3H, H_{10b} + 2CH DIEA) ; 3.73 (q, 6H, J = 7.0 Hz, H₂) ; 4.04 (m, 1H, H₈) ; 4.86 (s, 1H, H₁₁) ; 6.00 (d, 1H, J = 7.8 Hz, H₇) ; 6.27 (t, 1H, J = 5.5 Hz, H₆) ; 6.99 (s, 1H, H_{9a}) ; 7.22 (s, 1H, H_{9b}).

Compound 3:




Figure S6. ¹H NMR spectra of silylated leucinamide using DIEA as base

¹H RMN (500MHz, DMSO-d₆, 25°C): δ(ppm) 0.50 (m, 2H, H₃) ; 0.86 (t, 6H, J = 6.5 Hz, H₁₂) ; 1.14 (t, 9H, J = 7.0 Hz, H₁) ; 1.28 (m, 20H, CH₃ DIEA – H_{10a} – H_{10b}) ; 1.38 (m, 2H, H₄) ; 1.57 (m, 1H, H₁₁) ; 2.93 (m, 2H, H₅) ; 3.11 (m, 3H, CH₂ DIEA) ; 3.59 (m, 3H, 2CH DIEA) ; 3.73 (q, 6H, J = 7.0 Hz, H₂) ; 4.07 (m, 1H, H₈) ; 5.92 (d, 1H, J = 8.6 Hz, H₇) ; 6.04 (t, 1H, J = 5.8 Hz, H₆) ; 6.87 (s, 1H, H_{9a}) ; 7.32 (s, 1H, H_{9b}) ; 9.41 (s, 1H, NH⁺ DIEA).

Residual DIEA: 57%




Figure S7. ¹H NMR spectra of silylated leucinamide using NaHCO₃ as base

¹H RMN (500MHz, DMSO-d₆, 25°C): δ(ppm) 0.50 (m, 2H, H₃) ; 0.86 (t, 6H, J = 6.5 Hz, H₁₂) ; 1.14 (t, 9H, J = 7.0 Hz, H₁) ; 1.28-1.42 (m, H₄ - H_{10a} - H_{10b}) ; 1.57 (m, 1H, H₁₁) ; 2.93 (m, 2H, H₅) ; 3.73 (q, 6H, J = 7.0 Hz, H₂) ; 4.07 (m, 1H, H₈) ; 5.92 (d, 1H, J = 8.6 Hz, H₇) ; 6.04 (t, 1H, J = 5.8 Hz, H₆) ; 6.87 (s, 1H, H_{9a}) ; 7.32 (s, 1H, H_{9b}).

Compound 4:




Figure S8. ¹H NMR spectra of silylated argininamide using DIEA as base

¹H RMN (500MHz, DMSO-d₆, 25°C): δ(ppm) 0.52 (m, 2H, H₃) ; 1.14 (t, 9H, J = 7.0 Hz, H₁) ; 1.28 (m, 15H, CH₃ DIEA) ; 1.41 (m, 5H, H_{10a} - H_{10b} - H₄) ; 1.59 (m, 1H, H₁₂) ; 2.94 (m, 2H, H₅) ; 3.10 (m, 4H, CH₂ DIEA - H₁₁) ; 3.59 (m, 2H, 2CH DIEA) ; 3.73 (q, 6H, J = 7.0 Hz, H₂) ; 4.10 (m, 1H, H₈) ; 6.10 (d, 1H, J = 7.8 Hz, H₇) ; 6.22 (t, 1H, J = 5.5 Hz, H₆) ; 7.01 (s, 1H, H_{9a}) ; 7.45 (s, 1H, H_{9b}) ; 7.78 (t, 1H, J = 5.8 Hz, H₁₃) ; 9.49 (s, 1H, NH⁺ DIEA).

Residual DIEA: 50%




Figure S9. ¹H NMR spectra of silylated serinamide using NaHCO₃ as base

¹H RMN (500MHz, DMSO-d₆, 25°C): δ(ppm) 0.52 (m, 2H, H₃) ; 1.14 (t, 9H, J = 7.0 Hz, H₁) ; 1.41 (m, 5H, H_{10a} - H_{10b} - H₄) ; 1.59 (m, 1H, H₁₂) ; 2.94 (m, 2H, H₅) ; 3.10 (m, 2H, H₁₁) ; 3.73 (q, 6H, J = 7.0 Hz, H₂) ; 4.10 (m, 1H, H₈) ; 6.10 (d, 1H, J = 7.8 Hz, H₇) ; 6.22 (t, 1H, J = 5.5 Hz, H₆) ; 7.01 (s, 1H, H_{9a}) ; 7.45 (s, 1H, H_{9b}).

Compound 5:




Figure S10. ¹H NMR spectra of the synthesis of N-[3-tris(trimethylsiloxy)silylpropyl]-imidazole-1-carboxamide

¹H RMN (500MHz, DMSO-d₆, 25°C): δ(ppm) 0.08 (s, 27H, H₁) ; 0.46 (m, 2H, H₂) ; 1.55 (3, 2H, H₃) ; 3.20 (q, 2H, J = 5.8 Hz, H₄) ; 7.01 (m, 1H, H₈) ; 7.38 (s, 0.8H, traces of CDI) ; 7.66 (t, 1H, J = 1.5 Hz, H₇) ; 8.21 (t, 1H, J = 1.1 Hz, H₆) ; 8.30 (s, 0.4H, traces of CDI) ; 8.50 (t, 1H, J = 5.5 Hz, H₅).




Figure S 11. ²⁹Si NMR spectra of the synthesis of N-[3-tris(trimethylsiloxy)silylpropyl]-imidazole-1-carboxamide

²⁹Si RMN (99.4MHz, DMSO-d₆, 25°C): δ(ppm) 7.81

Compound 6:




Figure S12. ¹H NMR spectra of silylated isoglutamine

¹H RMN (500MHz, DMSO-d₆, 25°C): δ (ppm) 0.08 (m, 27H, H_1) ; 0.38 (m, 2H, H_2) ; 1.35 (m, 2H, H_3) ; 1.66 (m, 1H, H_{9a}) ; 1.66 (m, 1H, H_{9b}) ; 2.16 (t, 2H, $J = 8.0$ Hz, H_{10}) ; 2.93 (m, 2H, H_4) ; 4.09 (m, 1H, H_7) ; 5.98 (d, 1H, $J = 8.0$ Hz, H_6) ; 6.10 (t, 1H, $J = 5.6$ Hz, H_7) ; 7.00 (s, 2H, $\text{H}_{8a} - \text{H}_{11}$) ; 7.37 (s, 1H, H_{8b}).




Figure S13. ²⁹Si NMR spectra of silylated isoglutamine

²⁹Si RMN (99.4MHz, DMSO-d₆, 25°C): δ (ppm) 7.63